Loading clinical trials...
Loading clinical trials...
Feasibility of CSF (Cerebrospinal Fluid) and Plasma ctDNA (Circulating Tumor Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib
Conditions
Interventions
Plixorafenib
Cobicistat 150 MG [Tybost]
Locations
1
United States
Johns Hopkins
Baltimore, Maryland, United States
Start Date
April 7, 2025
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2027
Last Updated
December 10, 2025
NCT05639413
NCT04317599
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions